• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Germany·Healthcare·M3V.DE
Share

MeVis Medical Solutions AG Stocks

€ 23.4Last Updated 12.06.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

€ 49.56M

€ 23.4
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

MeVis Medical Solutions AG, a German enterprise established in Bremen in 1992 and operating as a subsidiary of Varex Imaging Deutschland AG, specializes in developing and marketing sophisticated software solutions. These solutions are designed for the in-depth analysis and evaluation of medical imaging data. The company serves a diverse client base across the United States and Europe, including manufacturers of medical devices, providers of healthcare IT platforms, and clinical end-users. A key focus for MeVis's software is the image-based early detection and diagnosis of significant public health conditions, such as breast, lung, liver, and neurological disorders. Their technology supports a broad spectrum of imaging modalities, including computed tomography, digital mammography, digital tomosynthesis, magnetic resonance imaging, and digital sonography. In addition to its primary software products, MeVis offers a comprehensive suite of services. This includes providing specialized software programming support to other medical technology companies, supplying skilled professionals like software developers, product and project managers, application specialists, and test engineers. The company also produces three-dimensional technical visualizations, delivers interactive online training to enhance clinicians' diagnostic proficiency, and develops internet-based applications specifically for teleradiology.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, 'expensive' on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.06.2026 16:01

Highlights in small-caps: record IPO in biotech, Wizz Air success, SpaceX effect

13.06.2026 13:01

An investment idea for all times, IPO of the year and how to keep emotions in check in the stock market

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

13.06.2026 01:40

Hope for peace with Iran and SpaceX lifted spirits: stocks rose for second straight day

13.06.2026 01:05

SpaceX shares rose in value by 19% on the first day of trading. Is it worth buying them?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026